Prostate-specific antigen (PSA) testing may not accurately pinpoint levels at which transgender women on estrogen therapy may be at risk of developing prostate cancer, according to data from the ...

Screening PSA levels at aged 65-69 may inform the decision to continue or discontinue prostate cancer screening after age 70 years, regardless of patient race and ethnicity. The absolute risks of ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on disease progression. Among patients with intermediate-risk prostate cancer, ...

A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...

Hormone therapy initiation depends on disease extent; some agents avoid testosterone flare, allowing ADT without Casodex in certain cases. Active surveillance is increasingly chosen for favorable ...

NEW YORK (Reuters Health) - On average, men's levels of prostate-specific antigen (PSA) decrease as their body mass index (BMI) rises, a new study shows. PSA is a marker for prostate cancer risk when ...

After surgical removal of the prostate to treat prostate cancer, clinicians monitor prostate specific antigen (PSA) levels.

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Prostate cancer screenings could save lives but experts warn of major risks - Prostate cancer is the most common cancer among ...

ATLANTA - Each year, millions of American men get a blood test known as a PSA, or prostate-specific antigen, test as part of their yearly checkup. PSA is a protein produced by the prostate gland. If a ...

Treatment outcomes for patients with Ga68-PSMA-PET prostate cancer (PC) with or without conventional imaging correlates. Validation of a digital pathology-based multimodal artificial intelligence ...